Impaired response to ET(B) receptor stimulation in heart failure: functional evidence of endocardial endothelial dysfunction?
Inotropic effects of selective ET(B) receptor stimulation depend on the functional integrity of the endocardial endothelium (EE), which is negative when it is intact and positive when it is damaged. These results have been attributed to the existence of two subtypes of ET(B) receptors in the heart: (i) ET(B1), located on the EE, decreases inotropy; (ii) ET(B2), located on myocardial cells, increases inotropy. In the present study we investigated the functional integrity of the EE in a heart failure (HF) model (doxorubicin-induced cardiomyopathy) by evaluating the contractile response to ET(B1) receptor stimulation. New Zealand White rabbits were treated with doxorubicin (DOX-HF, 1 mg/kg, iv, twice weekly for 8 weeks) or with saline. Contractile effects of increasing doses of a selective agonist of endothelial ET(B) receptors, IRL-1620 (10(-9) to 10(-6) M), were studied in papillary muscles (Krebs-Ringer: 1.8 mM CaCl2, 35 degrees C) from control (n = 10) and DOX-HF rabbits (n = 7). Isotonic and isometric twitches were recorded and analyzed. Reported parameters included active tension (AT) and maximum velocities of tension rise (dT/dt(max)) and decline (dT/dt(min)). On echocardiography, DOX-HF rabbits had increased left ventricular (LV) end-diastolic and end-systolic diameters and reduced ejection fraction (52% +/- 2% vs. 61% +/- 1%). Contrary to control papillary muscles, DOX-HF muscles showed a steady decrease in contractility between 1 and 4 Hz. In the control group, IRL-1620 induced dose-dependent negative inotropic and lusitropic effects that decreased at 10(-6) M: 26% +/- 3%, AT; 17% +/- 3%, dT/dt(max); and 16% +/- 5%, dT/dt(min). In the DOX-HF group, these effects were significantly reduced. At the same concentration, IRL-1620 decreased AT (8% +/- 3%) and dT/dt(max) (8% +/- 3%), without significantly affecting dT/dt(min). This study showed an impaired response to endothelial ET(B) receptor stimulation, providing for the first time strong evidence of the occurrence of EE dysfunction in the failing heart and further highlighting the potential use of ET(B) receptor stimulation as a marker of EE function.
Brás-Silva
Carmen
C
Department of Physiology, Faculty of Medicine, University of Porto, Portugal.
Fontes-Sousa
Ana Patrícia
AP
Moura
Cláudia
C
Areias
José Carlos
JC
Leite-Moreira
Adelino F
AF
D000818:Animals; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000494:pharmacology; D004452:Echocardiography; D004699:Endocardium / Q000502:physiology; D016232:Endothelins / Q000494:pharmacology; D004727:Endothelium / Q000502:physiology; D006321:Heart / Q000502:physiology*; D006333:Heart Failure / Q000209:etiology; D066298:In Vitro Techniques; D007537:Isometric Contraction / Q000187:drug effects; D007551:Isotonic Contraction / Q000187:drug effects; D008297:Male; D010210:Papillary Muscles / Q000187:drug effects; D010446:Peptide Fragments / Q000494:pharmacology; D011817:Rabbits; D044023:Receptor, Endothelin B / Q000502:physiology*; D013997:Time Factors
D016232:Endothelins; D010446:Peptide Fragments; D044023:Receptor, Endothelin B; C074308:sovateltide; D004317:Doxorubicin